Charles Divita III Sells 27,731 Shares of Teladoc Health (NYSE:TDOC) Stock

Teladoc Health, Inc. (NYSE:TDOC) CEO Charles Divita III sold 27,731 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the sale, the chief executive officer directly owned 364,784 shares of the company’s stock, valued at $2,002,664.16. The trade was a 7.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Teladoc Health Price Performance

Teladoc Health stock opened at $5.38 on Friday. Teladoc Health, Inc. has a 52 week low of $4.40 and a 52 week high of $9.77. The company’s 50 day moving average price is $5.62 and its two-hundred day moving average price is $7.06. The stock has a market cap of $958.90 million, a P/E ratio of -4.71 and a beta of 2.13. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. The company had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.Teladoc Health’s quarterly revenue was up .3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.28) earnings per share. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, equities analysts predict that Teladoc Health, Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. TD Cowen decreased their target price on Teladoc Health from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Wells Fargo & Company reduced their price target on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, February 26th. Barclays began coverage on shares of Teladoc Health in a report on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price objective for the company. Finally, Bank of America raised shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Thursday, February 26th. Six analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.72.

Institutional Trading of Teladoc Health

Several hedge funds have recently made changes to their positions in TDOC. Jupiter Asset Management Ltd. lifted its position in shares of Teladoc Health by 293.9% during the 4th quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock valued at $27,021,000 after buying an additional 2,880,008 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Teladoc Health by 23.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock worth $53,260,000 after acquiring an additional 1,325,106 shares during the last quarter. Trexquant Investment LP purchased a new stake in Teladoc Health in the 4th quarter worth about $9,156,000. Monaco Asset Management SAM raised its stake in Teladoc Health by 159.2% in the 4th quarter. Monaco Asset Management SAM now owns 1,956,947 shares of the health services provider’s stock valued at $13,699,000 after acquiring an additional 1,201,947 shares during the period. Finally, Allianz Asset Management GmbH raised its stake in Teladoc Health by 189.2% in the 3rd quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock valued at $12,518,000 after acquiring an additional 1,059,458 shares during the period. 76.82% of the stock is currently owned by institutional investors.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates (improvements to Q1–Q4 2026, FY2026 and FY2027), which narrows expected losses and helps valuation/earnings outlook. Zacks Research coverage
• Positive Sentiment: Deutsche Bank upgraded TDOC to Buy, citing BetterHelp momentum, AI initiatives and international expansion — contributing to renewed analyst interest that can lift demand. Deutsche Bank upgrade
• Positive Sentiment: Coverage pieces highlight an earnings beat and strategic plans (BetterHelp, AI, international) that have put TDOC back on investors’ radar and supported recent short‑term gains. Valuation analysis
• Neutral Sentiment: Market notes point to volatility and short‑term moves relative to the broader market — useful context for traders but not a direct company catalyst. Market note
• Negative Sentiment: JPMorgan lowered its price target from $9 to $7 and assigned a “neutral” rating — a reduction in expected upside that can weigh on sentiment even though the new target still implies upside from current levels. JPMorgan note
• Negative Sentiment: Insider selling: CEO Charles Divita III sold 27,731 shares at ~$5.49 (disclosed in an SEC filing), reducing his stake by ~7% — a sell by the CEO that some investors may view negatively. SEC filing

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.